OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
Follow-Up Questions
Who is the CEO of OSR Holdings Inc?
Mr. Kuk Hyoun Hwang is the Chairman of the Board of OSR Holdings Inc, joining the firm since 2020.
What is the price performance of OSRH stock?
The current price of OSRH is $0.5858, it has increased 1.82% in the last trading day.
What are the primary business themes or industries for OSR Holdings Inc?
OSR Holdings Inc belongs to Biotechnology industry and the sector is Health Care
